Indoco Remedies share news, announcements and annual reports
NSE: INDOCOBSE: 532612Pharmaceuticals & BiotechnologySmall Cap
Indoco Remedies Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 2005
Last close ₹208.30down ₹1.20 (0.57%)BSE ₹208.35
Share price at the NSE close on 30 Oct 2026. Previous close ₹209.50.
30 Oct: open ₹208.65, high ₹210.00, low ₹205.10
52-week range of traded prices to 30 Oct 2026
₹162.19Low, 30 Mar 2026₹288.00High, 6 Nov 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,923 Cr1,173rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 60.20
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹132 crore of one-off items, the largest of them in the quarter to Jun 2026.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.88
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.10%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 3.2%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹132 crore of one-off items, the largest of them in the quarter to Jun 2026.
- −10.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 1.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.96
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 64,72755.0% delivered
Indoco Remedies share news and announcements
729 announcements, routine notices left out, newest first. Page 15 of 15.
Oct 2008
21 Oct · Board meeting
Meeting of the Board of Directors scheduled for October 23, 2008 for considering inter-alia, the unaudited financial results for the second quarter ended September 30, 2008 has been rescheduled and will be held on October 31, 2008.14 Oct · Board meeting
Inter-alia, for considering the unaudited financial results for the second quarter period from July 01, 2008 to September 30, 2008.13 Oct · Meeting
Minutes of the Annual General Meeting of the members of the Company held on September 26, 2008. The copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Sep 2008
8 Sep · Meeting
Register of Members and Share Transfer Books of the Company will remain closed from September 23, 2008 to September 26, 2008 (both days inclusive) for purposes of the declaration of dividend and Annual General Meeting to be held on September 26, 2008.5 Sep · Dividend
At the adjourned meeting of the Board of Directors held on September 05, 2008 the Board has confirmed the proposal for recommendation of a dividend of Rs.5.00 per share (50%) for the financial year ended March 31, 2008 (9 months).4 Sep · Board meeting
Board Meeting of the Company convened today i.e. September 02, 2008 for consideration of audited financial results and declaration of dividend, if any, has been adjourned, and adjourned meeting will be held on September 05, 2008, for consideration of the audited financial results and declaration of dividend, if any, will be considered for the financial year ended March 31, 2008.
Aug 2008
20 Aug · Board meeting
Inter-alia, for considering the audited financial results for the financial year ended on March 31, 2008 and recommendation of dividend for the financial year 2007-2008.
Jul 2008
21 Jul · Board meeting
Inter alia, for taking on record the un-audited financial results for the first quarter ended June 30, 2008.
Apr 2008
21 Apr · Board meeting
Inter alia, to consider and take on record the unaudited financial results for third and the last quarter ended March 31, 2008.
Feb 2008
25 Feb · Management
Vide its letter dated February 23, 2008 that "The meeting of the Board of Directors of the Company held today, the Board has accepted the resignation of Mr. Atul S. Rajadhyaksha as Director w.e.f. 23.02.08 and has appointed Mr. Sharad P. Upasani as the Director w.e.f. 23.02.08 in the vacancy caused by the resignation of Mr. Atul S. Rajadhyaksha".25 Feb · Business
At the meeting of the Board of Directors of the Company held on February 23, 2008 the following have been approved by the Board: (1) Change of Company's financial year ending from June 30th to March 31st. Consequently, the financial year of the Company for 2007-08 will be for a 9 months' period from July 01, 2007 to March 31, 2008. (2) A Scheme of Amalgamation for a proposal to amalgamate Company's 100% subsidiary, Shree Herbal Technologies Ltd., with the Company.
Jan 2008
29 Jan · Board meeting
Vide its letter dated January 29, 2008, that: "At the meeting of the Board of Directors of Indoco Remedies Limited (IRL) held today, it has been decided to take up 100% equity stake in Shree Herbal Technologies Ltd (SHTL) for a consideration of Rs. 251.00 lacs. The investment will make SHTL a wholly owned subsidiary of Indoco. SHTL is an unlisted Company with registered office at Delhi. It was incorporated in 2005 and is yet to commence manufacturing operations. Indoco will leverage its manufacturing capacity from the investment".21 Jan · Board meeting
Inter-alia, for considering the unaudited financial results for the second quarter from October 01, 2007 to December 31, 2007.9 Jan · Meeting
Minutes of the Annual General Meeting held on December 22, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Nov 2007
23 Nov · Meeting
Register of Members and Transfer Books of the Company will be closed from December 15, 2007 to December 22, 2007 for the purpose of declaration of dividend @ 65% (Rs. 6.50 per share) and Annual General Meeting to be held on December 22, 2007.
Oct 2007
23 Oct · Board meeting
Inter-alia, for considering the unaudited financial results for the first quarter period from July 01, 2007 to September 30, 2007.18 Oct · Miscellaneous
Vide its letter dated October 18, 2007, that: "The Board of Directors of Indoco Remedies Ltd., at the meeting held today have approved a proposal for entering into a partnership arrangement with Amneal Corporation, New Jersey, U.S.A. to inter alia, develop and manufacture ophthalmic formulations for marketing it in the United States. This arrangement will help increase the future turnover and business of the company in the world's largest pharmaceutical market".18 Oct · Dividend
At the meeting of the Board of Directors of the Company held on October 18, 2007 have proposed a dividend of 65% for the financial year 2006-07.10 Oct · Board meeting
Inter-alia, for considering the audited financial results for the fourth quarter and financial year ended on June 30, 2007, and recommendation of dividend, if any, for the financial year 2006-2007.
Jul 2007
4 Jul · Results
Company shall publish Audited Financial Results within a period of 3 month for the year ended on June 30, 2007 i.e. on or before September 30, 2007.
Jun 2007
25 Jun · Minutes of meeting
Minutes of the Court Convened Extra Ordinary General Meeting of the shareholders of the Company held on June 18, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.1 Jun · Notice of Meeting
Notice of Court Convened Meeting of the Equity Shareholders of the Company together with the relevant explanatory statement, in connection with a Composite Scheme of Amalgamation/Merger and Demerger proposed between the Company and La Nova Chem (I) Pvt. Ltd and SPA Pharmaceuticals Pvt. Ltd. The copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2007
29 May · Notice of Meeting
By an Order dated May 04, 2007, the Hon'ble High Court of Judicature at Bombay, has directed that a meeting of the Equity Shareholders of Indoco Remedies Limited, the Applicant/Transferee Company/Resulting Company for the purpose of considering, and, if thought fit, approving, with or without modification, the arrangement embodied in the Composite Scheme of Amalgamation and Demerger between La Nova Chem (India) Private Limited (the "Transferor Company") and SPA Pharmaceuticals Private Limited (the "Demerged Company") and Indoco Remedies Limited (the "Applicant") and their respective shareholders and creditors (the "Scheme"). In pursuance of the said Order, the meeting of the Equity Shareholders of the Applicant/Transferee Company/Resulting Company will be held on June 18, 2007. A copy of the Notice of the Meeting published in the News Paper shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.17 May · Management
Mr. J. B. Salian has been appointed the Secretary of the Company w.e.f. 9th May 2007 in place of Mr. Anil Kale, who has left the employment with the Company.
Apr 2007
26 Apr · Management
April 26, 2007 that "at the just concluded meeting of the Board of Directors of the Company, the following items, inter-alia, were transacted; (1) The resignations of the following directors from the Board, were accepted; (a) Mr.S.Y.Rege. (b) Mr.P.K.Kakodkar. (2) The following persons were appointed as Additional Directors on the Board in terms of the provisions of Section 260 of the Companies Act, 1956. (i) Mr. Atul Rajadhyaksha (ii) Mr. Rajiv Kakodkar".17 Apr · Board meeting
Inter-alia, to take on record the un-audited Quarterly results for the period January 01, 2007 to March 31, 2007 and also un-audited results for the period July 01, 2006 to March 31, 2007.
Mar 2007
16 Mar · E-mail ID for Investor Complaints
The company has designated the e-mail ID i.e. compliance.officer@indoco.com, for the purpose of registration of complaints by investors and correspondence with them for redressel of their grievances.
Jan 2007
24 Jan · Business
January 24,2007 that: "At the meeting of Board of Directors of the Company held today, the following were approved: a) The unaudited financial results of the Company for the quarter ended 31.12.2006 were approved and taken on record by the Board of Directors. b) The amalgamation of the 100% subsidiary of the Company, viz. La Nova Chem (India) Pvt. Ltd., with the Company was approved. The Board also approved the Scheme of Amalgamation for that purpose. c) The acquisition of the pharmaceutical business of SPA Pharmaceuticals Pvt. Ltd., by legal demerger process, was approved. The Board also approved the scheme of amalgamation for that purpose. The Board approved an exchange ratio of 3 equity shares of Indoco Remedies Limited for every 4 equity shares of SPA Pharmaceuticals Pvt. Ltd., for the purpose of the said scheme".16 Jan · Board meeting
Inter-alia, for the follow:- (i) To take on record the un-audited Quarterly results for the second quarter period October 01, 2006 to December 31, 2006. (ii) To consider the amalgamation of M/s. La Nova Chem (India) Pvt. Ltd., a 100% subsidiary of the Company, with the Company. (iii) To consider the acquisition of the pharmaceutical business of M/s. SPA Pharmaceuticals Pvt. Ltd, Mumbai, by a legal demerger process.